GRI Bio, Inc. (GRI) Dividend History

Company News

• Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

  Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.

  GlobeNewswire Inc.

  Featured Companies: WINT
• GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

  GRI Bio, a biotechnology company, announced that the European Patent Office has issued a decision to grant a patent for its NKT cell modulator GRI-0803 and its library of over 500 proprietary compounds. The company is focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases.

  GlobeNewswire Inc.
• GRI Bio Announces Exercise of Warrants

  GRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.
• GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series - GlobeNewswire

  GRI Bio, a biotechnology company, announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024, where the CEO will provide a corporate overview and business outlook.

  GlobeNewswire Inc.
• GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

  GRI Bio, a biotechnology company, announced the release of interim data from its ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF). The CEO discussed the significance of the data and its implications for the company's IPF program.

  GlobeNewswire Inc.